glp 1 google scholar Frontiers Frontiers | Research progress of

Non-covalent small-molecule Kelch-like ECH-associated protein 1nuclear factor Erythroid 2-related Factor 2 (Keap1Nrf2) inhibitors and their potential for targeting central nervous system diseases

See which companies are preparing to go public and why investors are watching closely

Intravenous (IV)/ Intramuscular (IM) Therapy IV/IM Glutathione A most potent antioxidant (GAMMA-GLUTAMYL-CYSTEINYL-GLYCINE) Reduces oxidative damages Prevention and reversal of alcohol-induced fatty liver, cirrhosis, hepatitis, and liver tumors It May help to improve chronic inflammatory disease, It May help to improve autoimmune illness and conditions

Adipex and Suprenza (phentermine) Qsymia (phentermine-topiramate) Contrave (naltrexone-bupropion) Xenical and Alli (orlistat) Imcivree (setmalanotide) Plenity (carboxymethylcellulose hydrogel) Several additional agents are used off-label for weight loss at acceptable risk when prescribed thoughtfully and documented as off-label

Hernandez et al., 2018)

Cell 149 (5), 10601072